Monteagudo, Mònica http://orcid.org/0000-0002-8839-5056
Barrecheguren, Miriam
Solntseva, Iryna
Dhalwani, Nafeesa
Booth, Alison
Nuñez, Alexa
Lambrelli, Dimitra
Miravitlles, Marc http://orcid.org/0000-0002-9850-9520
Funding for this research was provided by:
AstraZeneca
Article History
Received: 2 October 2020
Accepted: 3 February 2021
First Online: 22 March 2021
Competing interests
: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols, and Novartis; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis, Sanofi, and Grifols; and research grants from GlaxoSmithKline and Grifols. M.B. has received speaker fees from Grifols, Menarini, CSL Behring, and GSK and consulting fees from GSK and Novartis. D.L., N.D., and A.B. are employees of Evidera. The authors confirm that there are no other conflicts of interest to report.